Dr. James H. Feusner
Claim this profileEpic Care-Dublin
Studies Breast Cancer
Studies Breast cancer
13 reported clinical trials
27 drugs studied
Area of expertise
1Breast Cancer
HER2 positive
Stage I
Stage II
2Breast Cancer
HER2 positive
Stage I
Stage II
Affiliated Hospitals
Clinical Trials James H. Feusner is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are being observed for cardiac toxicity. The largest cohort (currently open to accrual) is observational, and contains patients who are taking a beta blocker, ACE inhibitor, or ARB as well as their trastuzumab-based treatment. The goal is to understand how common cardiac problems are in this group of patients at high risk. The smaller cohort (currently closed to accrual) is randomized. Patients in this second cohort are randomized to either carvedilol or no treatment, with the goal of seeing whether carvedilol (used to treat heart failure and high blood pressure) may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
More about James H. Feusner
Clinical Trial Related8 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments James H. Feusner has experience with
- Carboplatin
- Biospecimen Collection
- Crizotinib
- Eflornithine
- Sulindac
- Cisplatin
Breakdown of trials James H. Feusner has run
Breast Cancer
Breast cancer
Colorectal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does James H. Feusner specialize in?
James H. Feusner focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are Stage I.
Is James H. Feusner currently recruiting for clinical trials?
Yes, James H. Feusner is currently recruiting for 2 clinical trials in Dublin California. If you're interested in participating, you should apply.
Are there any treatments that James H. Feusner has studied deeply?
Yes, James H. Feusner has studied treatments such as Carboplatin, Biospecimen Collection, Crizotinib.
What is the best way to schedule an appointment with James H. Feusner?
Apply for one of the trials that James H. Feusner is conducting.
What is the office address of James H. Feusner?
The office of James H. Feusner is located at: Epic Care-Dublin, Dublin, California 94568 United States. This is the address for their practice at the Epic Care-Dublin.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.